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Inﬂammatory responses mediated by activated microglia play a pivotal role in the pathogenesis of human immunodeﬁciency
virus type 1 (HIV-1)-associated neurocognitive disorders. Studies on identiﬁcation of speciﬁc targets to control microglia
activation and resultant neurotoxic activity are imperative. Increasing evidence indicate that voltage-gated K
þ (Kv) channels are
involved in the regulation of microglia functionality. In this study, we investigated Kv1.3 channels in the regulation of neurotoxic
activity mediated by HIV-1 glycoprotein 120 (gp120)-stimulated rat microglia. Our results showed treatment of microglia with
gp120 increased the expression levels of Kv1.3 mRNA and protein. In parallel, whole-cell patch-clamp studies revealed
that gp120 enhanced microglia Kv1.3 current, which was blocked by margatoxin, a Kv1.3 blocker. The association of gp120
enhancement of Kv1.3 current with microglia neurotoxicity was demonstrated by experimental results that blocking microglia
Kv1.3 attenuated gp120-associated microglia production of neurotoxins and neurotoxicity. Knockdown of Kv1.3 gene by
transfection of microglia with Kv1.3-siRNA abrogated gp120-associated microglia neurotoxic activity. Further investigation
unraveled an involvement of p38 MAPK in gp120 enhancement of microglia Kv1.3 expression and resultant neurotoxic activity.
These results suggest not only a role Kv1.3 may have in gp120-associated microglia neurotoxic activity, but also a potential
target for the development of therapeutic strategies.
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Human immunodeﬁciency virus type 1 (HIV-1) invades the
central nervous system (CNS) early in the course of infection
and provokes progressive cognitive, behavioral, and neuro-
logical impairments, which are now collectively referred to as
HIV-1-associated neurocognitive disorders (HAND).
1 HAND,
varying in severity from an asymptomatic to a mild neurocog-
nitive impairment and in its most serious form a devastating
dementia (HIV-associated dementia), develops in a subset
of individuals infected with HIV-1.
1 As HIV-1 infects mono-
nuclear phagocytes (brain perivascular macrophages and
microglia), but not neurons, in the CNS, the pathogenesis for
HAND is widely believed a consequence of indirect neuro-
toxicity. Ample evidence suggests that immune and inﬂam-
matory responses mediated by the activated microglia,
the predominant resident CNS immunocompetent cell type
productively infected by HIV-1, play a pivotal role in the
HAND pathogenesis.
1–3 As such, studies on how HIV-1
triggers microglia neurotoxic activities and identiﬁcation of
speciﬁc target(s) to regulate microglia activation and resultant
production of neurotoxins are highly imperative.
Voltage-gated potassium (Kv) channels have recently
gained attention as promising targets for therapy of immune-
and inﬂammation-mediated neurological disorders
4–6 and for
speciﬁc immunomodulation.
7 Electrophysiological studies of
microglia in cell culture and tissue slices have demonstrated
that microglia express several types of Kv channels including
inward and delayed rectiﬁer Kv channels and the expression
levels of these Kv channels in microglia undergo dramatic
changes during the process of activation.
8 Exposure to a
variety of activating stimuli produce a characteristic pattern
of upregulation of Kv1.3 currents
8–11 and elevated Kv1.3
channels appear to be associated with microglia activation
and neurotoxic activity.
8,12–14 Indeed, studies have shown
that activation of microglia results in neuronal injury through
a process requiring Kv1.3 activity in microglia and blocking
microglia Kv1.3 or decrease of Kv1.3 expression inhibits
microglia-associated neurotoxicity.
15,16 We hypothesize that
HIV-1 infection and/or HIV-1 glycoprotein 120 (gp120) can
activate microglia through enhancement of outward K
þ
current conducted by Kv1.3 channels, resulting in microglia
production of neurotoxins and consequent neuronal injury. To
test this hypothesis, we studied the effects of HIV-1 gp120 on
Kv1.3 current in primary rat microglia cultures. Our previous
studies have shown that gp120 increased the outward K
þ
current in cultured rat microglia, leading to neuronal injury
via CXCR4 and cAMP-dependent protein kinase A signaling
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17 In this study, we
examined the role of Kv1.3 in gp120-stimulated microglia
production of neurotoxins and resultant neuronal injury. Our
results revealed that incubation of rat microglia with gp120
signiﬁcantly increased microglia production of neurotoxins and
resultant neurotoxic activity. The neurotoxic activity induced
by gp120-stimulated microglia was signiﬁcantly attenuated
by a Kv1.3 channel blocker margatoxin (MgTx) or by siRNA
knockdown of microglia Kv1.3 gene. Further investigation
indicates an involvement of p38 MAP kinase (MAPK)
signaling in gp120-associated microglia neurotoxic activity.
Results
Enhancement of microglia Kv1.3 current by gp120. We
have previously showed that gp120 IIIB enhanced whole-cell
outward K
þ currents in cultured rat microglia.
17 To further
examine whether gp120 enhancement of microglia outward
K
þ current is conducted by Kv1.3 channels, we studied
the effects of gp120 IIIB on outward K
þ currents recorded in
microglia in the presence and absence of MgTx, a
speciﬁc Kv1.3 blocker. Incubation of microglia with gp120
for 2h signiﬁcantly enhanced the outward K
þ currents
with an average instantaneous outward K
þ current density
of 71.4±4.7pA/pF (Figure 1a, n¼9) when measured at
þ60mV. In comparison with the current density of 46.5±
1.6pA/pF (n¼12) recorded in control (Ctrl) microglia, the
difference was statistically signiﬁcant (Po0.01), conﬁrming
our previous ﬁnding that gp120 enhances outward K
þ
current in microglia. We separated the Kv1.3 current by
subtraction of the currents recorded in the presence of MgTx
(Figure 1b) from the whole-cell outward K
þ current. As
shown in Figures 1c and d, gp120 signiﬁcantly increased the
Kv1.3 currents recorded in rat microglia (Po0.01, n¼9). The
gp120-induced increase of outward K
þ currents was
blocked by MgTx in a concentration-dependent manner. At
concentrations (nM) of 0.1, 1, 10 and 100, MgTx blocked
10.3±4.3, 23.1±6.7, 64.9±3.8 and 93.5±6.7% of gp120-
induced increase of outward K
þ current, respectively,
indicating gp120 increases microglia outward K
þ current
via Kv1.3 (Figure 1e).
Gp120 upregulation of Kv1.3 expression in
microglia. Growing evidence indicate that activated
microglia express higher levels of Kv channels, especially
the Kv1.3. To assess the effect of gp120 on the levels of
Kv1.3 expression in microglia, we monitored mRNA abundance
and protein expression levels of gene-related Kv1.3 on rat
microglia. First, Kv1.3 mRNA expression was examined
using reverse transcription (RT)-PCR. Rat microglia were
exposed to gp120 (500pM) or LPS (0.5mg/ml, as a positive
control) for 24h. Using gene-speciﬁc primers, RT-PCR was
performed and standardized to a housekeeping gene
(b-actin) in each sample. As shown in Figure 2a, gp120
treatment increased expression levels of Kv1.3 mRNA in
microglia by 1.5-fold. Similar results were obtained
from microglia treated with LPS as positive controls, with
B1.9-fold increase of Kv1.3 mRNA expression. As mRNA
levels do not always correspond with protein expression, we
further examined the expression levels of Kv1.3 channel
proteins by western blot using a speciﬁc antibody against
Kv1.3. In parallel with the results unraveled by RT-PCR,
western blot analysis revealed increased levels of Kv1.3
protein expression by 1.5-fold and 2.3-fold in microglia
Figure 1 Enhancement of microglia Kv1.3 outward K
þ current by gp120.
(a) Whole-cell outward K
þ current traces recorded from a non-treated (Ctrl) microglia
anda different microglialcelltreated withgp120 (gp120). Voltageprotocol employedto
generate outward K
þ current isshown above the current traces(voltage step duration
is not in proportion to the current traces). (b)O u t w a r dK
þ currents recorded from the
same cells shown in a in the presence of 100nM MgTx (MgTx) or MgTx plus gp120
(MgTxþgp120). (c)K v1.3 currents obtained by subtraction of the currents in b
from the currents in a.( d) Instantaneous whole-cell current densities (WC) and
the instantaneous current densities carried by Kv1.3 channels (Kv1.3) recorded
in non-gp120-treated microglia (Ctrl) and gp120-treated microglia (gp120). Note
gp120 signiﬁcantly increased Kv1.3 current. *Po0.01. (e) gp120-induced increase
of K
þ outward current was blocked by MgTx in a dose-dependent manner
Figure 2 gp120 upregulation of microglia Kv1.3 expression. (a) Representative
gel showing RT-PCR products for Kv1.3 and internal control b-actin (Left). The
density of each band was normalized to its internal control and represented in a bar
graph (Right). Results reﬂect the increase of Kv1.3 mRNA was signiﬁcantly different
in LPS- (increasing 1.9-fold) or gp120- (increasing 1.5-fold) treated microglia when
compared with non-treated controls (Ctrl). (b) The left panel shows representative
western blot (Kv1.3, and b-actin). Right, each band density was normalized to
internalb-actincontrol.SigniﬁcantdifferencesweredetectedinLPS(increasing2.3-
fold) or gp120 (increasing 1.5-fold). *Po0.05 versus Ctrl; ***Po0.001 versus Ctrl
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Cell Death and Diseasetreated with gp120 and LPS, respectively (Figure 2b).
These results are in full agreement with our previous
observations that gp120 increased Kv1.3 protein expression
in cultured rat microglia as detected by western blot and
immunocytochemistry.
17
Involvement of Kv1.3 in microglia-induced
neurotoxicity. After demonstration of gp120 enhancement
of Kv1.3 expression and Kv1.3 current in microglia, we
questioned whether the elevated levels of Kv1.3 expression
and the enhancement of Kv1.3 current were involved
in microglia-induced neurotoxicity. To these ends, we
examined neuronal viability and neuronal apoptosis in a
microglia-neuronal co-culture system using MTT and TUNEL
assays and tested whether the neurotoxicity mediated
by gp120-pretreated microglia could be blocked by pre-
treatment of microglia with MgTx, 4-aminopyridine (4-AP) or
tetraethylammonium (TEA). In our early study, we found
gp120-treated microglia induced neuronal injury, which could
be attenuated by Kv channel antagonists.
17 To further
conﬁrm our previous observations, we examined neuronal
viability via MTT assay after co-culture of rat cortical neurons
with the microglia pretreated with gp120 at different
concentrations of 20, 200, 500 or 1000pM. Being
pretreated with gp120 for 24h, microglia plated on the
transwells were co-cultured with rat cortical neurons grown
on poly-D-lysine-coated coverslips in 24-well plates for
additional 24h. As shown in Figure 3a, no signiﬁcant
reduction of neuronal viability was induced by microglia
pretreated with 20 or 200pM of gp120 when compared with
the cell viability observed in non-gp120-pretreated controls
(Ctrl). However, when pretreated with 500 and 1000pM
gp120, microglia caused a signiﬁcant decrease of neuronal
viability, with an average of 72.9±0.8% (Po0.05) and
26.1±1.6% (Po0.001) of survival neurons, respectively.
The reduction of neuronal viability induced by gp120-
pretreated microglia was blocked by MgTx, 4-AP or TEA
(Figure 3a), suggesting Kv1.3 is involved in microglia-
associated neurotoxicity. As 500pM gp120 produced a
consistent and signiﬁcant decrease of neuronal survival,
this concentration was chosen in the following TUNEL assay
study and other studies reported in this paper.
The neurotoxicity induced by gp120-pretreated microglia
was also evaluated via TUNEL assay. Microglia used for
TUNEL studies were exposed to a speciﬁc Kv1.3 channel
blocker MgTx in different concentrations (1, 10, or 100nM),
4-AP (1mM) or TEA (5mM) for 30min before addition of
gp120 (500pM) to the culture media. After 24h, microglia
were washed three times and then co-cultured with cortical
neurons (0.1 10
6/well in 24-well plates) for another 24h.
Apoptotic neurons were evaluated by TUNEL staining and
visualized by confocal microscopy (Figure 3c) Our results
showed that neurons co-cultured with gp120-pretreated
microglia exhibited 37.2±10.9% of TUNEL positive cells.
In comparison with 7.7±4.4% of TUNEL positive neurons
co-cultured with non-gp120-pretreated microglia (control),
Figure 3 Involvement of Kv 1.3 in neurotoxic activity induced by gp120-pretreated microglia. Microglia were pre-exposed to Kv channel antagonists, 4-AP (1mM),
TEA(5mM)orMgTx(1,10,100nM)for30minbeforeadditionofgp120(500pM).Aftera24htreatment,microgliawerethenco-culturedwithneuronsforanadditional24hin
a transwell system. (a) Examination of microglia-induced neuronal injury by MTT assay. The reduction of cell viability induced by gp120-pretreated microglia was
concentration-dependent,withasigniﬁcantreductionat500and1000pM.Suchareductionofneuronalviabilitybygp120-pretreatedmicrogliawasblockedbybroadspectrum
Kv channel antagonists 4-AP and TEA or by a speciﬁc Kv1.3 channel blocker MgTx (10nM). (c) Apoptotic neurons were evaluated by TUNEL staining and visualized by
confocal microscopy at x400 original magniﬁcation. Scale bar equals 50mm. (b) Quantiﬁcation of apoptotic neurons was obtained by determining the percentage of TUNEL-
positivecells.Gp120-pretreated microgliaproduceda signiﬁcantincreaseof neuronalapoptosis,whichwas blocked eitherby MgTxin a dose-dependent manner,or by broad
spectrum Kv channel blockers 4-AP and TEA. The results are representative of three independent experiments performed in triplicate determinations. *Po0.05 and
***Po0.001 versus Ctrl;
#Po0.05 versus gp120 500pM
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Cell Death and Diseasethedifferencewasstatisticallysigniﬁcant(Po0.05).Exposure
of microglia to MgTx at 1, 10 and 100nM before pretreatment
of microglia with gp120 signiﬁcantly reduced the percentage
ofapoptoticneuronsto26.8±3.6,16.0±4.4and11.8±3.0%,
respectively (Figure 3b). Such a dose-dependent reduction of
neuronal apoptosis by MgTx suggests an involvement of
Kv1.3 in microglia-induced neuronal toxicity. Moreover,
exposure of microglia to 4-AP or TEA also reduced
microglia-induced neuronal apoptosis to 11.9±4.5 and
12.5±5.0%, respectively, further supporting the involvement
of Kv1.3 in neurotoxic activity induced by gp120-pretreated
microglia (Figures 3b and c).
Blockade of Kv1.3 reduces gp120-induced microglia
production of neurotoxins. It is widely accepted that
activated microglia produce neurotoxins such as cytokines,
chemokines, nitric oxide (NO) and reactive oxygen species
(ROS) resulting in neuronal injury. To understand the
mechanisms underlying the neurotoxic activity mediated by
gp120-treated microglia, we examined cytokine, chemokine,
NO and ROS production in gp120-treated microglia and
the blockade of microglia production of neurotoxins by Kv
channel antagonists. In these experiments, puriﬁed microglia
were exposed to gp120 (500pM) in the presence or absence
of Kv channel blockers 4-AP (1mM), TEA (5mM) or MgTx
(10nM) in the culture media (added 30min before the
addition of gp120). The culture supernatants were then
harvested 24h later and used subsequently for the detection
of bioactive molecules. As illustrated in Figures 4a and b, the
production levels of chemokines (cytokine-induced neutro-
phil chemoattractant-2(CINC-2) and CINC-3) and cytokines
(IL-1a, IL-6, and TNF-a) were signiﬁcantly increased in the
Figure 4 Blockade of gp120-activated microglia production of neurotoxins by Kv channel blockers. Microglia were pre-exposed to 4-AP (1mM), TEA (5mM) or MgTx
(10nM) before addition of gp120. After a 24h incubation, the supernatants were harvested for cytokines and NO analysis and the cells were subjected to measure ROS
production as a function of H2O2 levels. (a) Collected supernatants were subjected to cytokine array blots (RayBiotech). Ovals encompass replicated blots indicating the
coordinates of cytokines, CINC 2 (oval 1), CINC 3 (oval 2), IFN-g (oval 3), IL-1a (oval 4), IL-6 (oval 5), and TNF-a (oval 6). (b) Densitometric analysis of cytokine array blots
were achieved by digital image analysis with NIH Image J software, and mean densities±S.D. were determined for replicate determinations. Kv channel antagonists
signiﬁcantlyamelioratedcytokine(CINC2,CINC3,IL-1a,IL-6andTNF-a)productioningp120-activatedmicroglia.(c)NOproductionwasdeterminedbyusingGriessreagent
kit (Molecular Probes). Results, represented in bar graphs, showed that gp120 signiﬁcantly increased the levels of NO production, and such an increase was diminished by
either 4-AP, TEA or MgTx. (d) ROS production was measured using an Amplex Red assay. An elevated level of ROS production was reﬂected in Gp120-infected microglia
group. This increased ROS production was ameliorated by 4-AP, TEA or MgTx, respectively. ***Po0.001 versus Ctrl;
#Po0.05,
##Po0.01,
###Po0.001 versus
gp120-treated group
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Cell Death and Diseasesupernatants recovered from gp120-treated microglia in
comparison with the results obtained from the supernatants
recovered from non-gp120-treated microglia (control). The
gp120-induced production of bioactive molecules was
markedly (Po0.01) reduced by Kv1.3 blocker MgTx, or by
broad spectrum Kv channel blockers 4-AP and TEA,
suggesting the involvement of Kv1.3 in gp120-induced
microglia production of bioactive molecules. However,
gp120 did not enhance microglia production of interferon-g
(IFN-g), a cytokine was reported to be produced by
microglia
18,19 (Figures 4a and b). In addition to detection of
cytokine and chemokine production, we also measured NO
levels in microglia-conditioned media. Treatment of microglia
with gp120 signiﬁcantly increased NO production with an
average of 767±64nM when compared with 195±31nM
detected in matched controls. Addition of Kv channel
blockers signiﬁcantly reduced gp120-induced NO
production. The average concentration was 438±48,
300±34, or 312±35nM when 4-AP, TEA or MgTx was
added to the cultures, respectively (Figure 4c). In comparison
with the NO concentration detected from gp120-treated
microglia, the difference was statistically signiﬁcant
(Po0.01). Similar results were obtained in microglia ROS
production. As shown in Figure 4d, the amount of ROS
produced by gp120-treated microglia was 179.6±15.6% of
the control level (untreated microglia). Addition of 4-AP, TEA
or MgTx to the cultures signiﬁcantly decreased the levels
of ROS to 120.9±11.8, 115.6±8.3 or 121.1±11.7% of
the control level. These results indicate involvement of
Kv1.3 channels in gp120-induced microglia production of
neurotoxins.
Knockdown Kv1.3 gene abrogated neurotoxic activity of
gp120-stimulated microglia. To further conﬁrm the role
Kv1.3 had in neurotoxic activity mediated by gp120-
stimulated microglia, we exploited gene silencing using
siRNA knockdown Kv1.3 gene (KCNA3) in microglia.
Microglia were either transfected with Kv1.3-siRNA or
nonspeciﬁc GAPD control siRNA (control siRNA). After 48h
or 72h of transfection, microglia were incubated with or
without gp120 (500pM) for additional 24h. Expression of
Kv1.3 mRNA or protein was examined by RT-PCR or western
blot. As shown in Figure 5a, Kv1.3 mRNA expression in
gp120-stimulated microglia was efﬁciently inhibited after 48h
transfection with Kv1.3 siRNA, when compared with Kv1.3
mRNA expression in gp120-stimulated microglia transfected
Figure 5 Knockdown Kv1.3 by siRNA abrogated the neurotoxic activity of gp120-activated microglia. Microglia were transfected with siRNA targeting Kv1.3 (KCNA3) or
nonspeciﬁc GAPD control siRNA for 48 or 72h and stimulated with gp120 (500pM) for an additional 24h. Cells were harvested for preparation of mRNA (48h post-
transfection/24h gp120 stimulation) and proteins (72h post-transfection/24h gp120 stimulation). Supernatants were subjected to neuronal culture. Neuronal apoptosis
and viability assay were determined using TUNEL staining and MTT assay. (a) Representative gels show RT-PCR products for Kv1.3 mRNA and internal control b-actin
(up2rows),andwesternblotsshowKv1.3channelproteinandinternalcontrolb-actinproteinexpressionofmicroglia(bottom2rows).(b)KnockdownofKv1.3geneabolished
the neurotoxic activity induced by the culture supernatants recovered from gp120-activated microglia as evaluated by MTT assay. The collected supernatants (1:10 dilution)
were subjected to primary neuronal culture for 24h and percentage of survival neurons were evaluated by MTT assay. An increased viability was observed in neurons that
treated with supernatants collected 72h post-Kv1.3 siRNA transfection/24h post-gp120 stimulation when compared with neurons treated with supernatants collected 72h
post-control siRNA transfection/24h post-gp120 stimulation (Po0.05). Supernatant collected from post-transfection of control siRNA had no signiﬁcant effect on altering
neuronal viability in comparison with the neuronal viability induced by supernatant recovered from gp120-stimulated microglia without siRNA transfection. (c) Transfection of
microglia with siRNA targeting Kv1.3 gene inhibited the neurotoxic activity induced by the culture supernatants collected from gp120-activated microglia. In contrast, the
supernatants collected from microglia transfected with control siRNA (ctrl-siRNA) and then stimulated with gp120 (500pM) produced a notable increase of neuronal death.
Each experiment was done in triplicate and data were obtained from three experiments. *Po0.05 versus Ctrl,
#Po0.05 versus ctrl siRNA
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mRNA expression, Kv1.3 protein expression was also
diminished after 72h transfection. These results demon-
strated that transfection of microglia with Kv1.3 siRNA
inhibited gp120-stimulated increase of Kv1.3 expression.
As gp120-activated microglia induced neuronal apoptosis via
Kv1.3 (Figure 3), we next examined whether knockdown of
Kv1.3 gene suppresses the neurotoxic activity produced by
gp120-activated microglia. Supernatants, collected from
microglia pre-transfected with Kv1.3-siRNA for 72h and
then incubated with or without gp120 for additional 24h,
were added to rat cortical neuronal cultures at 1:10 ratio and
incubated for 24h before being analyzed by MTT assay and
TUNEL staining. Knockdown of Kv1.3 abolished neurotoxic
activity mediated by gp120-activated microglia as illustrated
by its signiﬁcant improvement of neuronal survival in MTT
assay study (Figure 5b). TUNEL staining revealed similar
results to the knockdown of Kv1.3 gene, which decreased
apoptotic neurons (Figure 5c). These results indicated that
knockdown of the Kv1.3 gene signiﬁcantly abrogated
neurotoxic activity of gp120-stimulated microglia.
gp120 enhanced Kv1.3 expression and resultant
microglia neurotoxic activity via p38 MAPK signaling.
The above results showed that gp120 induces microglia
neurotoxic activity by enhancing microglia Kv1.3 current
and resultant microglia production of neurotoxins. We
further analyzed potential intracellular signaling on gp120-
mediated upregulation of microglia Kv1.3 expression and
resultant microglia neurotoxic activity. Microglia were
exposed to gp120 (500pM) in the absence or presence
of 4-AP (1mM), TEA (5mM), MgTx (10nM) or SB203580
(SB, 10mM) for 24h. Immunocytochemistry, western blot
and TUNEL assay were performed to evaluate involve-
ment of p38 MAPK in microglia Kv1.3 expression and
microglia-induced neurotoxicity in microglia–neuronal
co-cultures. Our results showed that gp120-mediated
upregulation of Kv1.3 channel expression was associated
with activation of microglia p38 MAPK and blocking p38
MAPK by SB signiﬁcantly reduced the gp120-associated
upregulation of Kv1.3 expression (Figures 6a and b).
Pretreatment of microglia with SB also attenuated the
neurotoxic activity mediated by gp120-treated microglia as
demonstrated in a microglia-cortical neuronal transwell
co-culture system (Figure 6e). These results indicate an
involvement of p38 MAPK in intracellular signaling of gp120-
associated microglia neurotoxic activity. Another piece of
evidence supporting the involvement of p38 MAPK in gp120-
associated microglia neurotoxicity came from western blot
studies demonstrating gp120 upregulation of p38 MAPK
phosphorylation and the blockade of gp120-mediaed
upregulation of p38 MAPK phosphorylation by 4-AP, TEA
and MgTx (Figures 6c–e).
Discussion
HIV-1gp120 is a viral envelope glycoprotein with neurotoxic
activity in HIV-1-infected brains. It is shed off from virions and/
or secreted from HIV-1-infected macrophages and microglia.
This soluble viral protein has the potential to diffuse and
interact directly with surrounding and distant neural cells
possibly via chemokine receptor CXCR4,
20,21 or act indirectly
on local and distant neural cells by stimulating uninfected
microglia to produce neurotoxins. Whereas the indirect
mechanism of HIV-1-associated neuronal injury has widely
been studied, few have investigated the role of microglia Kv
channels, in particular the Kv1.3, in neurotoxic activity
mediated by gp120-activated microglia. We have previously
demonstrated that gp120 enhanced outward K
þ current in
cultured rat microglia via chemokine receptor CXCR4 and
cAMP-dependent PKA pathways.
17 Biological signiﬁcance of
gp120-inducedenhancementofmicrogliaoutwardK
þ current
was demonstrated by experimental results showing the
neurotoxic activity induced by gp120-pretreated microglia,
evaluated by TUNEL staining and MTT assays, was
signiﬁcantly attenuated by Kv channel blockers. These results
suggest that gp120 triggers microglia neurotoxic activity by
enhancing microglia outward K
þ current.
17 In the present
study, we further investigated the involvement of Kv channels
in neurotoxic activity induced by gp120-treated microglia and
its intracellular signaling pathways. Our results showed that
gp120 enhanced microglia Kv1.3 current and production of
cytokines, chemokines, NO and ROS resulting in microglia
neurotoxic activity. These ﬁndings were supported by experi-
mental results that cytokine production and neurotoxic activity
induced by gp120-treated microglia were blocked either by
Kv1.3antagonistsorbyknockdownofKv1.3geneinmicroglia.
The gp120-induced increase of microglia production of
neurotoxins and resultant neurotoxic activity was mediated
via p38 MAPK signaling.
In addition to being the target for HIV-1, soluble viral protein
gp120 and cytokines, microglia also function as a source of
neurotoxins in many infectious, inﬂammatory and degenera-
tive brain diseases as well as a source of neurotrophins in
normal brain.
13,22–24 Upon challenging, microglia undergo
dramatic phenotypic, immunochemical, and functional
changes, collectively referred to as ‘activation’ and the
activated microglia produce a variety of bioactive molecules
with potential toxicity to neurons. Ample evidence indicates
that immune and inﬂammatory responses mediated by
activated microglia have a pivotal role in the pathogenesis of
HAND.
2,3 Studies have shown that HIV-1-infected and
immune-activated microglia (andbrain macrophages) release
a number of soluble substances including, but not limited to,
pro-inﬂammatory cytokines, chemokines, excitatory amino
acids, NO and ROS, as well as viral proteins, which can
diffuse and injure surrounding and distant neurons, contribut-
ing to the HAND pathogenesis.
23,25 Therefore, it is important
to identify potential target(s) to regulate microglia activation
andtheirresultantproductionofneurotoxinsinordertocontrol
microglia-associated neurotoxicity.
In this study, we examined the involvement of Kv1.3 on
microglia production of chemokines, cytokines (the represen-
tative chemokines and cytokines analyzed are shown in
Figure 4b), NO and ROS. Our results showed gp120
stimulated microglia production of chemokines (CINC-2,
CINC-3) and cytokines (IL-1a, IL-6 and TNF-a, but not IFN-g),
as well as NO and ROS. The gp120-induced microglia
production of chemokines, cytokines, NO and ROS were
signiﬁcantly reduced by a speciﬁc Kv1.3 blocker MgTx in
gp120 induces microglia neurotoxicity via Kv1.3
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Cell Death and Diseaseaddition to its blockade by broad spectrum Kv channel
blockers 4-AP and TEA, suggesting an involvement of Kv1.3
inmicrogliaproductionofneurotoxicsubstancesandresultant
neurotoxicty. Interestingly, gp120 did not increase microglia
production of IFN-g, a cytokine expressed and produced by
microglia.
18,19,26 The failure of gp120 in increasing microglia
production of IFN-g may indicate microglia production of a
small amount of IFN-g or microglia may require other
mechanisms for full production of IFN-g and secrete it to the
culture supernatant.
18,19,26
Microglia expresses several types of Kv channels and the
levels of their expression undergo dramatic changes during
Figure 6 p38 MAPK is involved in gp120-mediated microglia upregulation of Kv1.3 expression and resultant neurotoxic activity. Microglia were exposed to gp120
(500pM), with or without 4-AP (1mM), TEA (5mM) MgTx (10nM) or SB203580 (10mM). Immunocytochemistry, western blot and TUNEL assay were performed after 24h
incubation for evaluationof microgliaKv1.3 expression and resultant neurotoxicactivity.(a) gp120enhancedthe expression levels of Kv1.3 in microgliaand this enhancement
was blocked by a p38 MAPK inhibitor SB203580 (SB). The microglia were stained with rat monoclonal Mac-1 (CD11b; 1:500 dilution, red), whereas Kv1.3 was stained with
rabbitpolyclonalantibody(1:200dilution,green).Imageswerevisualizedbyﬂuorescentmicroscopy.Representativeimagesshowedthatgp120enhancedKv1.3expression,
whichwasblockedbySB.(b)Westernblotanalysisillustratedthatthegp120enhancementofKv1.3expressioninmicrogliawasblockedbySB,demonstratinginvolvementof
p38MAPK in gp120-induced increase of Kv1.3 expression.(c) Further analysisby western blot revealed that gp120upregulatedp38 MAPKphosphorylation, with remarkable
effects during the ﬁrst 2h. (d) The blockade of gp120 upregulation of p38 MAPK phosphorylation by 4-AP, TEA or MgTx, suggests a link between Kv channel activation and
p38 MAPK phosphorylation. (e) A bar graph illustrating p-p-38/p-38 relative density. Note gp120 signiﬁcantly increased the relative density and the gp120-induced increase
wasattenuatedby4-AP,TEAorMgTx.***versusCtrl,Po0.001;
##versusgp120,Po0.01;
###versusgp120,Po0.001).(f)Neuronalapoptosisinducedbygp120-stimulated
microglia was signiﬁcantly attenuated (gp120-microglia versus SB: 33.8% versus 12.8%) by the treatment of gp120-stimulated microglia with SB, indicating that activation of
p38 MAPK is required for neurotoxic activity mediated by gp120-stimulated microglia. Data were presented as Mean±S.D. obtained from three independent experiments.
Compared with Control: *Po0.05 versus non-gp120-stimulated microglia (Ctrl);
#Po0.05 versus gp120-stimulated microglia
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Cell Death and Diseasethe process of activation.
8,13 The activated microglia
express Kv1.3 channels and Kv1.3 current was predominantly
detected in activated microglia,
27,28 suggesting a role for
Kv1.3 in regulating microglia function. It has been reported
that activated microglia kill neurons and blocking microglia
Kv1.3 channels inhibits microglia neurotoxicity,
15 indicating
the involvement of Kv1.3 in microglia-mediated neurotoxicity.
In an agreement with the aforementioned ﬁndings, our results
showed that gp120 elevated the levels of microglia Kv1.3
expression, enhanced Kv1.3 current, and increased microglia
production of cytokines and resultant neurotoxic activity,
which were blocked by a speciﬁc Kv1.3 blocker MgTx or by
siRNA knockdown of Kv1.3 gene. These results clearly
indicate the involvement of microglia Kv1.3 channels in the
neurotoxic activity mediated by gp120-pretreated microglia.
The intracellular signaling pathways underlying
gp120-Kv1.3-associated microglia neurotoxic activity are
largely unknown. Studies have shown that phosphorylation
(activation) of p38 MAPK is involved in the processes of
microglia/macrophage activation, leading to pro-inﬂammatory
cytokine production and neuronal death.
3,15,29,30 Thus,
inactivation of p38 MAPK pharmacologically or genetically
would diminish or abolish microglia/macrophage-associated
neurotoxic activity.
31 Indeed, inhibition of p38 MAPK phos-
phorylation by a speciﬁc blocker SB203580 prevents gp120-
associated neuronal death in mixed neuronal-glial cultures.
31
In an attempt to explore whether p38 MAPK is involved in
gp120-associatedelevationofmicrogliaKv1.3expressionand
resultant neurotoxic activity, we examined effects of
SB203580, a speciﬁc p38 MAPK inhibitor, on gp120
enhancement of microglia Kv1.3 expression and effects of
MgTx on p38 MAPK phosphorylation. Our results revealed
gp120 upregulation of Kv1.3 expression resulting in neuronal
apoptosis via p38 MAPK as inhibition of p38 MAPK by
SB203580 blocked gp120 upregulation of Kv1.3 expres-
sion and resultant neurotoxic activity. We also observed
gp120 enhancement of microglia p38 phosphorylation
and pretreatment of microglia with MgTx attenuated
gp120-induced p38 phosphorylation. These ﬁndings are
in agreement with those reports showing the activation of
p38 MAPK as a requirement for microglia/macrophage in
gp120-induced neurotoxicity.
31–33
It has been shown that Kv channel blockers have promising
effects in the treatments of multiple sclerosis, spinal cord
injury cognitive decline.
34–36 The US Food and Drug Admin-
istration has recently approved Dalfampridine (Ampyra), a Kv
channel blocker, as a treatment to improve walking in
patients with multiple sclerosis (http://www.fda.gov/News
Events/Newsroom/PressAnnouncements/ucm198463.htm).
These shedlight onthe futureto useKv1.3 blockers tocombat
against HAND and other neurodegenerative disorders
in which microglia-associated immune and inﬂammatory
responses are involved in their pathophysiological processes.
Although the pharmacological blockade of microglia Kv1.3
channels might generate therapeutic beneﬁt, it might also
have the risk of causing immune suppression as Kv1.3 is
expressed in T cells.
7,28 However, as Kv1.3 is mainly expre-
ssed in human effector memory T cells (CD4
þCCR7
 
CD45RA
 ), which mediate Th1 cell inﬂammatory res-
ponse,
7,37 blocking Kv1.3 pharmacologically may have, if
any, limited effects on immunity because innate immune
response, Th2 cell response, B-cell immunity and immunolo-
gical synapse formation are basically not affected.
37,38
Indeed, speciﬁc blockers of Kv1.3 are being investigated as
therapeutics for diverse autoimmune disorders involving
effector memory T cells. Several lines of evidence indicate
that suppression of T effector memory cells by Kv1.3 does not
increase susceptibility to infection nor compromise immune
responses to vaccination,
39,40 although this will have to be
thoroughly investigated in the future.
In the scenario of HIV-1 brain infection, the pathogenesis of
HAND involves immune and inﬂammatory responses, which
are orchestrated by cells of the innate immune system,
namely microglia and macrophages. Activated microglia and
macrophages release neurotoxins resulting in neuronal
damage and cognitive impairment as seen in patients with
HAND. Our results clearly demonstrated that gp120 stimu-
lates microglia production of neurotoxins leading to neuronal
injury via microglia Kv1.3. Thus, to minimize and/or prevent
microglia/macrophage production of neurotoxins and resul-
tant neuronal injury, which may occur in HIV-1-infected brain,
it is most likely achievable to minimize and/or prevent
microglia/macrophage production of neurotoxins and resul-
tant neuronal injury by blocking microglia Kv1.3 with speciﬁc
blockers. As there is very limited information available on how
the Kv1.3 can be ‘best’ utilized for optimal therapeutic beneﬁt,
our ﬁndings might have potential signiﬁcance in the develop-
ment of therapeutic strategies for HAND, and perhaps other
neurodegenerativedisorders.Althoughmuchworkremainsto
bedone to bring speciﬁcKv1.3 blockers tothe clinic, the future
is encouraging.
Materials and Methods
Materials. HIV-1gp120 IIIB was purchased from Immunodiagnostics, Inc.
(Woburn, MA, USA). Aliquots of gp120 were kept as 100nM stock solution at
 801C. The stock solution was diluted to desired concentrations with artiﬁcial
cerebrospinal ﬂuid (ACSF) 2–5min before test. All chemicals, unless otherwise
speciﬁed, were from Sigma (St. Louis, MO, USA).
Isolation and puriﬁcation of rat microglia and neurons. Highly
puriﬁedmicrogliawerepreparedfromcerebralcorticesof1–2daysoldneonatalrats
and neuronal cultures were prepared from day 18 embryonic Sprague–Dawley rats
(Charles River Laboratories, Wilmington, MA, USA). The cortical tissues were dissected
in cold Hanks’ Balanced Salt solution (Gibco, Grand Island, NY, USA) and digested with
0.25% trypsin (Invitrogen, Carlsbad, CA, USA). Isolated cells were suspended under
different culture conditions to differentiate into neurons or microglia. For neuronal
differentiation, isolates were seeded at a density of 0.10 10
6 cells per well in
24-well plates or 1.0 10
6 cells per well in poly-D-lysine-coated 6-well-plates and
maintained for 10 days in neurobasal medium supplemented with 2% B27, 1%
penicillin/streptomycin and 0.25mM L-glutamine (Invitrogen). The purity of neuronal
cells (490%) was determined by staining with microtubule-associated protein-2
(1:1000, Chemicon International, Temecula, CA, USA) antibody.
For microglia differentiation, isolated cells (30 10
6) were plated into T75cm
2
ﬂasks in high-glucose Dulbecco’s modiﬁed Eagle’s medium (Life Technologies,
Grand Island, NY, USA) supplemented with 10% fetal bovine serum, 2mM
L-glutamine, 1% penicillin/streptomycin, and 1mgml
–1 macrophage colony-
stimulating factor. After 10 days in culture, ﬂasks were gently shaken to detach
microglial cells to culture media. The culture media were then plated in a fresh T75
ﬂaskfor30minat 371C. Thesuspensoryglialcellswerethenremovedviachanging
culture media. The resulting culture was 98–100% microglia as determined
by staining with OX-42 antibody (Serotec, Oxford, UK), a marker for microglia
CR3/CD11b receptors. All animal-use procedures were reviewed and approved
by the Institutional Animal Care and Use Committee (IACUC) of the University of
Nebraska Medical Center (# 00-062-07).
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þ currents were recorded from
primary rat microglia cultures at room temperature (RT, B221C). The microglia
cells were perfused with oxygenated (bubbled with 95% O2,5 %C O 2) ACSF
contained (in mM): 140 NaCl, 5 KCl, 2.0 CoCl2, 1 MgCl2,1 0D-glucose, 10 HEPES
(pH 7.4 adjusted with NaOH, osmolarity: 310mOsm). Patch-clamp electrodes,
made from borosilicate glass capillaries, had tip resistance of 4–8MO when ﬁlled
with pipette solution contained (in mM): 135 K-gluconate, 10 KCl, 1 CaCl2, 1 MgCl2,
10 EGTA, 0.5 Tris-GTP, 2 Mg-ATP, 10 HEPES (Adjusted pH to 7.3 with KOH,
osmolarity:300mOsm).Afterestablishmentofthewhole-cellconﬁguration,thecells
were allowed to stabilize for 3–5min before recording. The recorded cells were
voltage-clamped at  60mV and whole-cell outward K
þ current was induced by
voltage steps from the holding potentialof  60 to  40mV in the ﬁrst step and then
stepped to þ60mV in increments of 10mV. The seal resistance was 1–10GO.
Junction potentials were corrected and the cell capacitance was compensated
(B70%) in most cells. Current signals were ampliﬁed with an Axopatch 200B
ampliﬁer, ﬁltered at 1kHz and digitized at 5kHz using a Digidata 1440A digitizer.
The current and voltage traces were displayed and recorded in a Dell computer
using pClamp 10.1 data acquisition/analysis system. The outward K
þ current
density (pA/pF) was calculated by dividing the cell capacitance from the peak
current generated by a voltage step.
TUNELandMTT assays. Neuronalapoptosisweredetectedusingthein situ
cell death detection kit, AP (Roche Applied Science, Indianapolis, IN, USA)
according to the manufacturer’s instructions. Brieﬂy, pretreated microglia,
at a density of 0.5 10
6 cells per transwell inserts (pore diameter, 1mm,
BD Biosciences, Franklin Lakes, NJ, USA), were co-cultured with cortical neurons
growing on poly-D-lysine-coated coverslips at a density of 1.0 10
5cells per well in
24-well plates. After a 24h incubation, microglia were removed, neurons were
washed and ﬁxed with 4% paraformaldehyde, followed by permeabilizing with 0.1%
Triton X-100. Neurons were then processed for TUNEL staining (green). ProLong
Gold antifade reagent (Molecular Probes, Eugene, OR, USA) with 40,60-diamidino-
2-phenylindol (DAPI) was added to stain neuronal nuclei and mount coverslips.
Cells were visualized by Zeiss LSM 510 META NLO microscope (Zeiss
MicroImaging, Inc., Thornwood, NY, USA) in a 40  oil-immersion objective.
Apoptotic neurons (green ﬂuorescent cells) were counted and normalized to the
totalnumberofcellsasdeterminedbyDAPInuclearstain.ForMTTassays,neurons
after co-cultured with pretreated microglia were washed in PBS and then incubated
with fresh neuronal culture media containing MTT (500mg/ml) for 3h. At the end of
the incubation period, the MTT solution was replaced with 500ml of dimethyl
sphingosine for cell lyses, and the optical density (OD) of absorption was then
measured at 570nm.
Detection of oxidative stress. To assess hydrogen peroxide (H2O2)
production from activated microglia, ROS and NO were monitored as an indication
of H2O2 accumulation using an Amplex Red Hydrogen Peroxide/Peroxidase Assay
Kit or a Griess reagent kit (Molecular Probes), respectively. Pre-treated microglia
seeded at 1 10
5 cells per well in a 96-well ﬂuorometer plate were incubated with
Krebs-Ringer buffer containing 50mM Amplex Red reagent, 1Uml
–1 horseradish
peroxidase (HRP) for 30min at 371C. Fluorescence was measured using a
ﬂuorescence microplate reader (BioTek Instruments, Winooski, VT, USA) with
excitationat 530nmanddetectionat 580nm.Backgroundﬂuorescencedetermined
at 0min incubation for a non-H2O2 control reaction was subtracted. For NO
production, supernatants (50ml) collected from pre-treated microglia were mixed
with 50ml of the sulfanilamide solution, 50ml of NED solution and then incubated
for 30min at RT. The OD of reactants was measured at 520 and 540nm using
an ELISA plate reader (Model: SpectraMAX 190, Molecular Devices).
Immunocytochemistry. Pretreated microglia growing on poly-D-lysine-
coated coverslips at a density of 0.5 10
6 per well in 24-well plates were ﬁxed
with 4% PFA for 30min, followed by the addition of blocking/permeabilization
solution (10% normal goat serum, 0.2% Triton X-100 and 0.1M glycine) for
additional 30min. At the end point, primary Abs, including rat monoclonal Ab Mac-1
(CD11b; 1/500; Serotec) and rabbit polyclonal Ab Kv1.3 (1:100, Alomone Labs,
Jerusalem, Israel), were added to coverslips for 1h at RT. Cells were subsequently
incubated with Alexa Fluor 488 and Alexa Fluor 594-conjugated secondary Abs
(1:1000, Invitrogen; Molecular Probes) for 1h after wash. ProLong Gold antifade
reagent with DAPI (Molecular Probes) was used for neuron nuclei staining. Images
wereobtainedby a ZeissLSM 510 METANLO microscope in a 40  oil-immersion
objective. A minimum of ﬁve images were taken from each slides.
Western blot analyses. Membrane or total proteins were prepared using a
Membrane Protein Extraction Kit (BioVision, Mountain View, CA, USA) or a RIPA
Buffer (Bio-Rad, Hercules, CA, USA). For membrane protein preparation, microglia
were lysed in a Homogenize Buffer Mix supplemented with protease Inhibitor
Cocktail (1:500, BioVision) for 30min on ice. The lysates were centrifuged in
700 g for 10min at 41C and the supernatants were then transferred to new vials
and centrifuged at 10000 g for 30min at 41C. The pellets, total cellular membrane
proteins, were re-suspended in0.5% TritonX-100 inPBS before use.For total proteins
extraction, microglia or neurons were suspended in RIPA buffer containing protease
inhibitor and centrifuged at 8000 g for 10min at 41C. The clariﬁed lysates were
transferred to fresh tubes on ice for analysis. Membrane proteins of 20mg and
20mg total proteins were separated by electrophoresis on 4–15% Tris-HCl gels and
transferred to polyvinylidene diﬂuoride membranes. Membranes were blocked with
5% dry milk in Tris-Buffered Saline (TBS) (all from Bio-Rad Laboratories) and probed
overnight at 41C with primary Abs including rabbit polyclonal Kv1.3 (1:200; Alomone
Labs, Israel), phospho-p38 MAPK and p38 MAPK (1:1000; Cell Signaling Technology,
Danvers, MA, USA), anti-mouse b-actin monoclonal antibody (1:10000, Sigma-
Aldrich). Membranes were washed (four times, 10min each) in TBS with 0.2%
Tween (TBS-T) and incubated with HRP-conjugated anti-rabbit, or anti-mouse
secondary antibody (1:10000, Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) for 1h at RT. Labeled proteins were visualized by Pierce
ECL Western Blotting Substrate (Thermo Scientiﬁc, Rockford, IL, USA). Band
densities of phospho-p38 were normalized to total p38 in each sample.
Cytokine arrays. Cytokine assays were performed using Cytokine Antibody
Array1(RatAntibodyArrayI;RayBiotech,Inc.,Norcross,GA,USA)accordingtothe
manufacturer’s instructions. Membranes pre-coated with cytokine antibody were
blocked by a blocking buffer at RT for 30min, then equal volumes of supernatants,
collected from microglia pretreated with gp120 (Immunodiagnostic, Inc., Woburn,
MA, USA) in the presence or absence of 4-AP or TEA, were added to replace the
blocking buffer and incubated over night at 41C. After washing three times with
wash bufferI andtwo timeswith washbuffer II, eachmembranewas incubatedwith
biotin-conjugated antibodies for 2h and followed by a HRP-conjugated streptavidin
at RT for 30min. Membranes were developed by Detection buffer C and D mixture
and visualized by exposure of the array to X-ray ﬁlm. Densitometry analysis of the
array was performed using the NIH Image J software.
Reverse transcription-PCR. Total RNA was isolated from microglia using
TRIzol Reagent (Invitrogen) and puriﬁed by RNeasy Mini Kit (QIAGEN, Inc.,
Valencia,CA,USA). TotalRNAof 10mgwas reversetranscribed at651Cfor 50min
according to SuperScript III reverse transcriptase (Invitrogen). PCR ampliﬁcation
was conducted using a Gene-Amp PCR 2400 system (PerkinElmer, Toronto,
Canada)withPlatinumPCRSuperMix(Invitrogen).ThePCRmixturewasincubated
for 2min at 941C, subjected to 30 cycles consisting of a 30s denaturing phase at
941C, a 30s annealingphase at 551C, a 1min extensionphase at 721C, anda ﬁnal
extension phase of 10min at 721C. The resulting DNA products were resolved on
1.5% agarose gels containing 0.5mgml
–1 ethidium bromide. Densitometry analysis
of products was measured using the Northern Eclipse 6.0 software (Bio-Rad) and
normalized to each internal control b-actin. PCR primers were as follows: Kv1.3:
forwardprimerwas50-GTACTTCGACCCGCTCCGCAATGA-30;reversewas50-GG
GCAAGCAAAGAATCGCACCAG. b-Actin: forward primer was 50-GTGGGGCGCC
CCAGGCACCA-30; reverse was 50-CTTCCTTAATGTCACGCACGATTTC-30.
siRNA transfection. Pre-designed siRNA on target plus SMART pool against
Rat KCNA3 (Kv1.3, NM-019270) mRNA was purchased by Dharmacon, Inc.
(Chicago, IL, USA). Microglia at a density of 2 10
6 cell per well in 6-well plates
weretransfectedwith100mlof2mMsiRNAfor48or72hinthepresenceofDharma
FECT Transfection Reagent (Dharmacon, Inc.) according to the manufacturer’s
instructions. A nonspeciﬁc control siRNA, on-target plus GAPD control pool (rat)
(Dharmacon, Inc.) was also transfected at the same concentration as the control.
After transfection, microglia were stimulated with gp120 (500pM) or without gp120
stimulation for 24h, then supernatants were collected for TUNEL and MTT assay
and microglia were harvested for preparation of RNA and protein.
Statisticalanalysis. Experimental data are expressedasmean±S.E.unless
otherwise indicated. Statistical analyses were performed by Student t-tests.
A minimum P-value of 0.05 was estimated as the signiﬁcance level for all tests.
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